Moderate Atopic Dermatitis
‘Will make life better’: FDA advances Zoryve cream 0.05% for pediatric atopic dermatitis
The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years, according to a press release from the manufacturer.
Arcutis submits sNDA for Zoryve cream 0.05% to treat AD in children aged 2 to 5 years
Arcutis Biotherapeutics has submitted a supplemental new drug application to the FDA for Zoryve cream 0.05% for the treatment of pediatric mild to moderate atopic dermatitis, according to a press release.
Moderate-to-Severe Atopic Dermatitis: Separating Fact From Myth in Primary Care
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Getting Under the Skin: Updates in the Treatment of Pediatric Atopic Dermatitis
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Quality of life affected more by psycho-cognitive factors than disease severity
NEW ORLEANS — In an analysis of psoriasis and eczema patients, psycho-cognitive factors proved to impact quality of life more than objective disease severity.